Search

Search Constraints

You searched for: Author/Creator Fury, Matthew

Search Results

1. 428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). (10th December 2020)

3. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. Issue 3 (11th February 2019)

4. OncoTree: A Cancer Classification System for Precision Oncology. (2021)

7. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (22nd May 2021)

8. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony‐Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (22nd May 2021)

9. Poster 202: Patellar Stabilization Procedures Not Performed to Address Alta Decrease Patellar Height. Issue 7 (30th July 2022)